Pancreatic Cancer Research

ResearcherZhejiang Cancer HospitalActive in the last 2 years

Xing Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8886-2777; OpenAlex author ID A5100701022. Sources: OpenAlex.

Their work

Papers
12 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2020: 3 papers · 2021: 3 papers · 2022: 4 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 12

  1. Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. First author DOI 10.1186/s13046-025-03323-9↗
  2. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. First author DOI 10.1038/s41467-023-38578-3↗
  3. Subtyping for pancreatic cancer precision therapy. Co-author DOI 10.1016/j.tips.2022.03.005↗
  4. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. First author DOI 10.1136/jitc-2021-004129↗
  5. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. First author DOI 10.1186/s13046-022-02273-w↗
  6. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Co-author DOI 10.1186/s40779-022-00416-w↗
  7. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. First author DOI 10.1038/s41467-021-24769-3↗
  8. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Co-author DOI 10.1186/s12943-021-01310-0↗
  9. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. First author DOI 10.1186/s13046-021-02055-w↗
  10. Calreticulin couples with immune checkpoints in pancreatic cancer. Co-author DOI 10.1002/ctm2.10↗
  11. Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. Co-author DOI 10.1038/s41392-020-0209-8↗
  12. Split Cyclin-Dependent Kinase 4/6-Retinoblastoma 1 Axis in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2020.602352↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 11 shared papers, 2020–2025 · strength 2.14
  2. Gang Zhang · 8 shared papers, 2020–2023 · strength 1.58
  3. Tianyu Tang · 6 shared papers, 2020–2023 · strength 1.03
  4. Xueli Bai · 3 shared papers, 2021–2025 · strength 0.61
  5. Zhengtao Hong · 2 shared papers, 2022–2025 · strength 0.49
  6. Xueli Bai · 2 shared papers, 2020 · strength 0.31
  7. Enliang Li · 2 shared papers, 2021 · strength 0.31
  8. Xiaozhen Zhang · 2 shared papers, 2020–2021 · strength 0.28
  9. Lingyue Liu · 1 shared paper, 2022 · strength 0.16
  10. Jinyuan Song · 1 shared paper, 2022 · strength 0.16
  11. Jiaqi Yang · 1 shared paper, 2022 · strength 0.16
  12. Xiao Zhi · 1 shared paper, 2022 · strength 0.16
  13. Junming Huang · 1 shared paper, 2022 · strength 0.16
  14. Jian Xu · 1 shared paper, 2021 · strength 0.12
  15. Dipesh Kumar Yadav · 1 shared paper, 2021 · strength 0.12
  16. Mengyi Lao · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.